[go: up one dir, main page]

SV2003000752A - Combinacion de agonistas de gaba e inhibidores de aldosa-reductasa ref. pc11830/700020/bb - Google Patents

Combinacion de agonistas de gaba e inhibidores de aldosa-reductasa ref. pc11830/700020/bb

Info

Publication number
SV2003000752A
SV2003000752A SV2001000752A SV2001000752A SV2003000752A SV 2003000752 A SV2003000752 A SV 2003000752A SV 2001000752 A SV2001000752 A SV 2001000752A SV 2001000752 A SV2001000752 A SV 2001000752A SV 2003000752 A SV2003000752 A SV 2003000752A
Authority
SV
El Salvador
Prior art keywords
profarmaco
aldosa
reductasa
ref
inhibitors
Prior art date
Application number
SV2001000752A
Other languages
English (en)
Inventor
Mylari Banavara Lakshman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SV2003000752A publication Critical patent/SV2003000752A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN COMBINACIONES DE UN AGONISTA DE GABA, UN PROFARMACO DEL MISMO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE DICHO AGONISTA DE GABA O DICHO PROFARMACO Y UN ARI, UN PROFARMACO DEL MISMO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE DICHO ARI O DICHO PROFARMACO, ESTUCHES QUE CONTIENEN TALES COMBINACIONES EN EL TRATAMIENTO DE MAMIFEROS, INCLUIDOS LOS SERES HUMANOS, QUE PADECEN COMPLICACIONES DE LA DIABETES TALES COMO NEUROPATIA DIABETICA, NEFROPATIA DIABETICA, CARDIOMIOPATIA DIABETICA, RETINOPATIA DIABETICA, MICROANGIOPATIA DIABETICA, MACROANGIOPATIA DIABETICA, CATARATAS O ULCERAS EN LOS PIES.
SV2001000752A 2000-11-30 2001-11-30 Combinacion de agonistas de gaba e inhibidores de aldosa-reductasa ref. pc11830/700020/bb SV2003000752A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25044800P 2000-11-30 2000-11-30

Publications (1)

Publication Number Publication Date
SV2003000752A true SV2003000752A (es) 2003-01-13

Family

ID=22947799

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000752A SV2003000752A (es) 2000-11-30 2001-11-30 Combinacion de agonistas de gaba e inhibidores de aldosa-reductasa ref. pc11830/700020/bb

Country Status (34)

Country Link
US (1) US6720348B2 (es)
EP (1) EP1337272A2 (es)
JP (1) JP2004514700A (es)
KR (1) KR20030059287A (es)
CN (1) CN1477976A (es)
AP (1) AP2001002359A0 (es)
AR (1) AR031432A1 (es)
AU (1) AU2002215160A1 (es)
BG (1) BG107812A (es)
BR (1) BR0115776A (es)
CA (1) CA2430309A1 (es)
CR (1) CR6962A (es)
CZ (1) CZ20031387A3 (es)
DO (1) DOP2001000294A (es)
EA (1) EA200300433A1 (es)
EC (1) ECSP034629A (es)
EE (1) EE200300249A (es)
HR (1) HRP20030419A2 (es)
HU (1) HUP0302555A3 (es)
IL (1) IL155710A0 (es)
IS (1) IS6787A (es)
MA (1) MA26965A1 (es)
MX (1) MXPA03004871A (es)
NO (1) NO20032387D0 (es)
OA (1) OA12413A (es)
PA (1) PA8534201A1 (es)
PE (1) PE20020598A1 (es)
PL (1) PL365378A1 (es)
SK (1) SK6092003A3 (es)
SV (1) SV2003000752A (es)
TN (1) TNSN01170A1 (es)
UY (1) UY27044A1 (es)
WO (1) WO2002043763A2 (es)
ZA (1) ZA200303340B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US6696407B1 (en) * 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US20030162754A1 (en) * 2001-12-17 2003-08-28 Tufts University Use of GABA and GABAB agonists
AU2003243603A1 (en) * 2002-06-13 2003-12-31 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
PT1572173E (pt) * 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
US20080318908A1 (en) * 2002-12-17 2008-12-25 Trustees Of Tufts College Use of gaba and gabab agonists
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
EP2314289A1 (en) * 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP2009533368A (ja) 2006-04-11 2009-09-17 ノバルティス アクチエンゲゼルシャフト 有機化合物
WO2008077597A1 (en) * 2006-12-22 2008-07-03 Novartis Ag 1-aminomethyl- l- phenyl- cyclohexane derivatives as ddp-iv inhibitors
US8273746B2 (en) 2007-03-23 2012-09-25 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
EP2309858A4 (en) 2008-07-31 2011-09-14 Dekel Pharmaceuticals Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
PL2326632T3 (pl) * 2008-09-06 2017-10-31 Bionevia Pharmaceuticals Inc Nowy kokryształ choliny i epalrestatu
WO2012088525A2 (en) 2010-12-23 2012-06-28 The Board Of Regents Of The University Of Texas System Methods for treating copd
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN107847548B (zh) * 2015-05-18 2022-06-14 贝思以色列女会吏医学中心公司 P物质、肥大细胞脱颗粒抑制剂和周围神经病
JP7171611B2 (ja) * 2017-04-21 2022-11-15 スティーブン・ホフマン 網膜症を治療するための組成物及び方法
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US12433904B2 (en) 2019-04-17 2025-10-07 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
CN116235853B (zh) * 2022-12-28 2025-11-04 中国农业大学 一种植物生长调节剂及其在促进植物生长、提高植物产量和增强植物抗逆性中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
US4130714A (en) 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
JPS5625169A (en) 1979-06-01 1981-03-10 Wellcome Found Triazine derivative
JPS5745185A (en) 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
JPS5740478A (en) * 1980-08-22 1982-03-06 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative
US4791126A (en) 1980-08-22 1988-12-13 Ono Pharmaceutical Co., Ltd. Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredients
FR2492258A1 (fr) 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
CA1176269A (en) 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4436745A (en) 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4438272A (en) 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5066659A (en) 1984-10-30 1991-11-19 Pfizer Inc. Spiro-heteroazalones for treatment of diabetic complications
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
GB8524663D0 (en) 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
AU602641B2 (en) 1986-04-17 1990-10-18 Senju Pharmaceutical Co., Ltd. Thiolactam-N-acetic acid derivatives, their production and use
EP0264586B1 (en) 1986-08-28 1991-04-03 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes
US4771052A (en) * 1987-02-05 1988-09-13 Hoechst-Roussel Pharmaceuticals, Inc. Tetrahydropyrido[3',4':4,5]pyrrolo[2,3-c]quinolines and their use as hypotensive agents
GB8801037D0 (en) 1988-01-18 1988-02-17 Plessey Co Ltd Improvements relating to fuel supply systems
US5252572A (en) * 1988-02-03 1993-10-12 Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. Pyridopyrimidine derivatives, pharmaceutical compositions containing them and process for preparing same
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US4980357A (en) 1990-03-01 1990-12-25 Pfizer Inc. Azolidinedione derivatives
US5037831A (en) 1990-05-21 1991-08-06 American Home Products Corporation Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
US5236945A (en) * 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
GB9016978D0 (en) 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
FR2774908B1 (fr) * 1998-02-17 2000-06-23 Centre Nat Rech Scient Utilisation d'inhibiteur de la liberation du glutamate dans le traitement de l'ischemie retinienne
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6350769B1 (en) * 1999-02-24 2002-02-26 The Regents Of The University Of California Gaba alpha receptors mediate inhibition of T cell responses
ATE264311T1 (de) * 1999-04-01 2004-04-15 Pfizer Prod Inc Verbindungen zur behandlung und vorsorge bei diabetes
AU782344C (en) * 1999-04-08 2006-08-17 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders

Also Published As

Publication number Publication date
JP2004514700A (ja) 2004-05-20
HUP0302555A2 (hu) 2003-11-28
HUP0302555A3 (en) 2005-06-28
WO2002043763A3 (en) 2003-03-13
UY27044A1 (es) 2002-07-31
OA12413A (en) 2004-09-30
US20020077319A1 (en) 2002-06-20
TNSN01170A1 (fr) 2005-11-10
BR0115776A (pt) 2004-01-13
KR20030059287A (ko) 2003-07-07
CZ20031387A3 (cs) 2004-04-14
AP2001002359A0 (en) 2001-12-31
PA8534201A1 (es) 2002-10-24
PL365378A1 (en) 2005-01-10
BG107812A (bg) 2004-02-27
NO20032387L (no) 2003-05-27
AR031432A1 (es) 2003-09-24
HRP20030419A2 (en) 2004-08-31
US6720348B2 (en) 2004-04-13
ECSP034629A (es) 2003-07-25
ZA200303340B (en) 2004-04-30
CA2430309A1 (en) 2002-06-06
AU2002215160A1 (en) 2002-06-11
EE200300249A (et) 2003-10-15
CN1477976A (zh) 2004-02-25
EP1337272A2 (en) 2003-08-27
DOP2001000294A (es) 2002-08-30
WO2002043763A2 (en) 2002-06-06
CR6962A (es) 2004-02-02
NO20032387D0 (no) 2003-05-27
IL155710A0 (en) 2003-11-23
MXPA03004871A (es) 2003-08-19
EA200300433A1 (ru) 2003-10-30
MA26965A1 (fr) 2004-12-20
IS6787A (is) 2003-04-14
SK6092003A3 (en) 2004-07-07
PE20020598A1 (es) 2002-07-08

Similar Documents

Publication Publication Date Title
SV2003000752A (es) Combinacion de agonistas de gaba e inhibidores de aldosa-reductasa ref. pc11830/700020/bb
SV2003000751A (es) Combinacion de agonistas de gaba e inhibidores de sorbitol-deshidrogenasa ref.pc11829/700017/bb
CY1112387T1 (el) Θεραπευτικη συνθεση περιεχουσα τουλαχιστον ενα παραγωγο της πυρρολοβενζοδιαζεπινης και φλουδαραβινη
PA8559501A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
UY26296A1 (es) Tratamiento medicamentoso del síndrome de piernas inquietas
UY27418A1 (es) Formulaciones en combinación de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilización
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
PA8803201A1 (es) Derivados acidos de cicloalquilamino
EA200400689A1 (ru) Фармацевтические и косметические композиции, содержащие ароматические альдегиды, содержащие оксигруппу
AR109263A2 (es) Composición que comprende moxidectina
BRPI0212298B8 (pt) composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
MX2007000117A (es) Una composicion de combinacion.
AR030957A1 (es) Composiciones de analgesico y glucosamina
ECSP066685A (es) Composición que comprende un extracto acuoso de hojas de vid roja y un agente que mejora la circulación sanguínea para el tratamiento de insuficiencias venosas crónicas
ATE399558T1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
SE0203817D0 (sv) New composition
UY28449A1 (es) Mezclas fungicidas
ECSP034673A (es) Compuestos de azole como agentes anti-fungicos
AR029718A1 (es) Composicion farmaceutica a base de cocaetileno y su utilizacion para el tratamiento de la dependencia de las substancias psicoactivas
CO5680380A2 (es) Mezclas fungicidas para combatir patogenos del arroz
CO5670339A2 (es) Mezclas fungicidas
AR027152A1 (es) Composicion farmaceutica para el tratamiento de la enfermedad cerebrovascular cognitiva.
CL2004000633A1 (es) Compuestos copolimeros, composicion farmaceutica que los contiene y procedimiento de preparacion, utiles en el tratamiento de enfermedades metabolicas oseas.